This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Thomas C. Neylan, MD; Bruce A. Wright, MD; M. D. Shelton, MD, PhD; Daniel P. van Kammen, MD, PhD
Western Psychiatric Institute and Clinic 3811 O'Hara St Pittsburgh, PA 15213-2593 and Department of Veterans Affairs Medical Center Highland Drive Pittsburgh, PA 15206

Arch Gen Psychiatry. 1990;47(2):192.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

Chandler¹ raises an objection to the research method of Lieberman et al,² in which stable schizophrenics were withdrawn from antipsychotic medications and monitored for signs of relapse. He suggests that drug discontinuation studies are unethical. Lieberman et al countered, correctly, that neuroleptics have unacceptable side effects, are ineffective in approximately 30% of patients, and that some patients can remain drugfree for many years without relapse.³

As a group that is involved in similar relapse prediction studies, we are very sensitive to the objection raised by Dr Chandler. It is our experience that this discomfort, articulated in the name of ethics, is unfortunately shared by many health care professionals treating schizophrenic patients. Although we agree with Lieberman et al, we feel that an additional response is indicated.

We believe that this so-called ethical objection is misguided. It reflects an underlying paternalism, which ignores the fact . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?